Clavister (CLAV) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
22 Nov, 2025Executive summary
Order intake surged 190% year-over-year to 110.3 MSEK, mainly due to a major 68 MSEK defense order from BAE Systems and strong civilian firewall business momentum.
Net sales grew 21% year-over-year to SEK 53.4 million, despite significant negative FX impacts.
Hardware shipments increased 111% year-over-year, supporting future recurring software license revenues.
Order book expanded to SEK 356 million from SEK 300 million in the previous quarter.
Series 9/TO9 warrant exercise achieved a 98.9% exercise rate, raising 63 MSEK and strengthening cash position for debt reduction.
Financial highlights
Gross margin was 75.2%, below the 80% target due to higher hardware sales but remained resilient.
Adjusted EBITDA margin was 12.6% (target 20%), impacted by sales mix and increased OpEx for growth investments.
FX-adjusted net sales growth was 24% year-over-year.
ARR grew 8% year-over-year to 133.9 MSEK, with a one-off churn effect from legacy contract transitions and a 5.6 MSEK negative impact from end-of-life platforms.
Operational cash flow improved to 5.0 MSEK, with better working capital management and a cash balance of 63.8 MSEK.
Outlook and guidance
Targeting at least 20% CAGR revenue growth for 2025–2027.
2025 ambition: EBITDA margin ≥20%, positive EBIT, and positive operational cash flow despite increased sales and marketing investments.
Expectation of higher gross margins in coming quarters as hardware mix normalizes.
Anticipated ramp-up in defense deliveries in the second half of the year, with additional contracts contributing from late 2025.
Positive ARR impact from Q1 hardware deliveries expected to materialize mainly in Q2.
Latest events from Clavister
- Record order intake, strong defense wins, and improved financials drive future growth.CLAV
Q4 202512 Feb 2026 - Q2 net sales up 17% to 45M SEK, with strong order intake and positive cash flow.CLAV
Q2 202423 Jan 2026 - First positive EBIT, record margins, and strong order growth drive robust momentum.CLAV
Q3 202416 Jan 2026 - Double-digit growth, robust tech, and major defense contracts position for strong 2025 expansion.CLAV
ABGSC Investor Days12 Jan 2026 - Q4 net sales up 23% and ARR up 14.4%, with improved margins and strong order backlog.CLAV
Q4 202424 Dec 2025 - Order intake up 52%, net sales up 22%, and gross margin at 81.1% with major defence wins.CLAV
Q2 202523 Nov 2025 - Record profitability and 15% sales growth, but supply delays impact near-term targets.CLAV
Q3 20256 Nov 2025